Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.4AZA Bioscience has entered into a licensing agreement with Gilead Sciences to research and develop compounds for the potential treatment of hepatitis C; a therapeutic area representing a significant unmet medical need.
Subscribe to our email newsletter
Under the terms of the agreement, 4AZA will grant to Gilead an exclusive, worldwide license for the research, development and commercialization of certain novel compounds for the potential prevention and treatment of hepatitis C viral infections (HCV).
Gilead will pay an upfront licensing fee and make an equity investment in its new partner company. 4AZA will also receive milestone payments based on the achievement of certain development and regulatory goals, should one or more compounds be advanced into clinical development, and a royalty of net sales of any marketed product resulting from the collaboration.
Additionally, Gilead will provide funding to 4AZA to support research staff to synthesize new compounds that may have potential activity against HCV. 4AZA will retain rights to develop and commercialize certain compounds evaluated under the companies’ agreement for other indications.
“The compounds discovered by 4AZA represent a new class of compounds with the potential of inhibiting HCV replication by a novel mechanism,” said Dr William Lee, Gilead’s senior vice president of research.